Insider Selling: Intercept Pharmaceuticals, Inc. (ICPT) CEO Sells 40,000 Shares of Stock
Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) CEO Mark Pruzanski sold 40,000 shares of the firm’s stock in a transaction dated Monday, June 26th. The shares were sold at an average price of $130.80, for a total value of $5,232,000.00. Following the sale, the chief executive officer now owns 611,718 shares in the company, valued at $80,012,714.40. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.
Mark Pruzanski also recently made the following trade(s):
- On Monday, April 3rd, Mark Pruzanski sold 1 shares of Intercept Pharmaceuticals stock. The shares were sold at an average price of $115.00, for a total value of $115.00.
Shares of Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) traded up 0.80% on Wednesday, hitting $122.99. The stock had a trading volume of 494,614 shares. Intercept Pharmaceuticals, Inc. has a 1-year low of $96.63 and a 1-year high of $177.93. The firm’s 50-day moving average is $116.91 and its 200 day moving average is $114.33. The stock’s market cap is $3.08 billion.
Intercept Pharmaceuticals (NASDAQ:ICPT) last issued its quarterly earnings results on Thursday, May 4th. The biopharmaceutical company reported ($3.61) earnings per share (EPS) for the quarter, beating the consensus estimate of ($4.27) by $0.66. Intercept Pharmaceuticals had a negative return on equity of 116.30% and a negative net margin of 825.58%. The firm had revenue of $21 million for the quarter, compared to analyst estimates of $15.88 million. During the same period in the previous year, the company posted ($5.17) earnings per share. The company’s quarterly revenue was up 4566.7% compared to the same quarter last year. Equities analysts forecast that Intercept Pharmaceuticals, Inc. will post ($14.50) EPS for the current year.
ILLEGAL ACTIVITY NOTICE: This report was first posted by American Banking News and is the property of of American Banking News. If you are reading this report on another domain, it was stolen and republished in violation of international copyright law. The original version of this report can be read at https://www.americanbankingnews.com/2017/06/28/insider-selling-intercept-pharmaceuticals-inc-icpt-ceo-sells-40000-shares-of-stock.html.
A number of institutional investors have recently modified their holdings of the stock. WFG Advisors LP raised its position in shares of Intercept Pharmaceuticals by 197.1% in the fourth quarter. WFG Advisors LP now owns 2,956 shares of the biopharmaceutical company’s stock valued at $103,000 after buying an additional 1,961 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of Intercept Pharmaceuticals by 14.4% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,047 shares of the biopharmaceutical company’s stock valued at $118,000 after buying an additional 132 shares in the last quarter. US Bancorp DE purchased a new position in shares of Intercept Pharmaceuticals during the first quarter valued at about $130,000. Quantbot Technologies LP purchased a new position in shares of Intercept Pharmaceuticals during the first quarter valued at about $170,000. Finally, Ladenburg Thalmann Financial Services Inc. raised its position in shares of Intercept Pharmaceuticals by 39.6% in the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 1,630 shares of the biopharmaceutical company’s stock valued at $178,000 after buying an additional 462 shares in the last quarter. Hedge funds and other institutional investors own 84.35% of the company’s stock.
Several equities research analysts recently commented on the company. Wedbush reiterated an “outperform” rating and set a $231.00 target price on shares of Intercept Pharmaceuticals in a report on Friday, June 23rd. BidaskClub upgraded Intercept Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Friday, June 23rd. Credit Suisse Group set a $201.00 target price on Intercept Pharmaceuticals and gave the company a “buy” rating in a report on Saturday, June 3rd. ValuEngine upgraded Intercept Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Friday, June 2nd. Finally, Citigroup Inc. set a $240.00 target price on Intercept Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday, February 28th. Three equities research analysts have rated the stock with a sell rating, five have issued a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock presently has an average rating of “Hold” and an average price target of $190.98.
Intercept Pharmaceuticals Company Profile
Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.
Receive News & Ratings for Intercept Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.